SCHEMBL10293116

SCHEMBL10293116

O=C(NCCC1CCOCC1)c1cc2cc(S(=O)(=O)N3CCCCCC3)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.51
TGM2 P21980 1/20 0.49
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 3/20 0.46
BACE1 P56817 2/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 2/20 0.45
HSD17B10 Q99714 1/20 0.45
ACHE P22303 1/20 0.45
CNR1 P21554 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8276708 0.91 ALDH1A1 (0.52) NAMPTTGM2ALDH1A1MEN1KMT2A
SCHEMBL10293203 0.91 ALDH1A1 (0.58) NAMPTALDH1A1MEN1HTTKMT2A
SCHEMBL10293105 0.87 GAA (0.45) NAMPTTGM2ALDH1A1KMT2AKDM4E
SCHEMBL8275562 0.82 KMT2A (0.52) NAMPTALDH1A1MEN1HTTKMT2A
SCHEMBL1156053 0.81 BACE1 (0.51) TGM2ALDH1A1MEN1HTTKMT2A
SCHEMBL10260510 0.81 NAMPT (0.52) NAMPTTGM2ALDH1A1MEN1HTT
SCHEMBL8278405 0.81 KDM4E (0.63) NAMPTALDH1A1HTTKMT2AKDM4E
SCHEMBL10293122 0.80 NAMPT (0.59) NAMPTALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL10293176 0.80 ALDH1A1 (0.61) ALDH1A1MEN1HTTKMT2AKDM4E
SCHEMBL10293112 0.80 ALDH1A1 (0.61) ALDH1A1MEN1HTTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C NAMPT 2751/4885TGM2 4178/4885ALDH1A1 3826/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C NAMPT 2751/4885TGM2 4178/4885ALDH1A1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.